Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":352627277,"tweetId":"352627277","gmtCreate":1616971147699,"gmtModify":1634523421161,"author":{"id":3567197540496772,"idStr":"3567197540496772","authorId":3567197540496772,"authorIdStr":"3567197540496772","name":"JazzyTizzy","avatar":"https://static.tigerbbs.com/cae924dd1adb7370389532002d192148","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ok</body></html>","htmlText":"<html><head></head><body>Ok</body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/352627277","repostId":1114428323,"repostType":4,"repost":{"id":"1114428323","kind":"news","pubTimestamp":1616771427,"share":"https://www.laohu8.com/m/news/1114428323?lang=&edition=full","pubTime":"2021-03-26 23:10","market":"us","language":"en","title":"Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1114428323","media":"seekingalpha","summary":"At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.In some cases, the opportunity is even better now, in others, it may be time to lock in some gains.In the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index started to decl","content":"Summary\n<ul>\n <li>At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.</li>\n <li>In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.</li>\n <li>In some cases, the opportunity is even better now, in others, it may be time to lock in some gains.</li>\n</ul>\n<img src=\"https://static.tigerbbs.com/b2d4b3c6dfc0c9c3580bdfc40f4151fb\" tg-width=\"1536\" tg-height=\"1025\">Photo by VeranikaSmirnaya/iStock via Getty Images\nWe wrote an article at the end of December in which we showcased 10 attractive income stocks that traded at inexpensive valuations back then. This resulted in a combination of upside potential and above-average income for investors that bought these stocks at the time. In this article, we will look again at the same ten stocks to see what has changed and whether they are all still attractive at current valuations.\nTop 10 Value Picks For Dividend Investors\nOur choices in&nbsp;our original article&nbsp;included the following 10 stocks:\n- Bristol-Myers Squibb (BMY) and AbbVie (ABBV) in healthcare\n- MPLX (MPLX) and Enterprise Products (EPD) in energy\n- Prudential (PRU) and Citigroup (C) in financials\n- Simon Property Group (SPG) and W. P. Carey (WPC) in real estate\n- AT&amp;T (T) in telecommunication\n- Intel (INTC) in tech\nLooking back one quarter later, we see that shares have performed like this:\n<img src=\"https://static.tigerbbs.com/efdd2ae3235c94c5e041ed4f3925d561\" tg-width=\"635\" tg-height=\"555\">Data by YCharts\nYear-to-date, they delivered an average return of 12% and a median return of 15%. Contrast this with the year-to-date return of 3% that was delivered by the S&amp;P 500 index (SPY), and we see that our picks clearly outperformed the broad market, delivering 4-5 times the performance enjoyed by those that put their money into the index.\n2020 Versus 2021: Growth Versus Value\nThis was, I believe, partially the result of investing in high-yielding stocks that traded at very inexpensive valuations and were thus undervalued, but the portfolio also benefited from an overall shift in the market's focus.\n2020 was the year of growth stocks, which saw many \"growthy\" tech names generate very attractive gains. The same could be said about EV stocks, renewable stocks, etc., which all flourished last year thanks to an appetite for growth stocks and unprecedented monetary stimulus. In 2021, that has changed to some degree:\n<img src=\"https://static.tigerbbs.com/5a81cfc9a5d54fce53409f7ea5cd0975\" tg-width=\"635\" tg-height=\"470\">Data by YCharts\nIn the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index (NASDAQ:QQQ) started to decline, underperforming the S&amp;P 500 index this year, whereas the less techy, less growth-focused Dow Jones index (NYSEARCA:DIA) has beaten the S&amp;P 500 so far in 2021. Looking at two ETFs that focus on either Value (VTV) or Growth(NYSEARCA:VUG), we see that the value theme clearly has been the winner so far this year, beating all three indexes, whereas the growth-themed ETF is down this year. The good news is that our basket of stocks still easily outperformed the Value ETF, which shows that we seem to have at least some skill when it comes to picking individual stocks (or maybe we got lucky).\nAre Those 10 Still Great Buys Today?\nSince some of these stocks have moved so much already in the first three months, they may not all be an opportune buy any longer, which is why we will take a quick look at all ten individually.\n1. AbbVie\nAbbVie was one of our two healthcare picks in the original article. The company combines many positives, including an above-average yield, a low valuation, and steady growth even during the pandemic. AbbVie's most recent quarterly results showcase its outstanding resilience during the current crisis: The company managed to grow its revenues across its portfolio, with Humira, Imbruvica, and its new drugs Skyrizi and Rinvoq&nbsp;showing&nbsp;a strong performance.\nEven better, the company guided earnings above consensus, forecasting earnings per share of $12.40 for the current year. Relative to its share price of $103, this means that shares got even cheaper since our December article, they are now trading for just 8.3 times forward earnings. In short, there is nothing not to like, and I believe that 5.1%-yielding AbbVie is a&nbsp;strong buy.\n2. Bristol-Myers Squibb\nBristol-Myers is the other healthcare pick in our original list. Like AbbVie, its shares were very inexpensive in December, and like AbbVie, it has continued to deliver strong operational results. Its most recent quarterly update included a 39% revenue growth rate compared to the previous year's quarter. This was impacted by one-time items from the Celgene takeover, but even adjusted for that, revenue growth came in at a strong 10% year over year.\nLike AbbVie, Bristol-Myers has also increased its earnings per share guidance for 2021, now forecasting profits of ~$7.30&nbsp;per share. Since shares are essentially flat since the beginning of the year, investors get an even better deal right now in terms of Bristol-Myers' valuation, which stands at 8.3 times net profits right now. Bristol-Myers is also one of the stocks Berkshire Hathaway (BRK.A)(BRK.B)&nbsp;has continued to add to&nbsp;in the most recent quarter, which indicates that this is indeed a strong pick for value investors.\n3. MPLX\nMPLX is a natural gas midstream player that offered a great income yield in December, at almost 13%. On top of that, shares were very inexpensive, trading at a distributable cash flow yield of almost 19%.\nLike many other energy-related names, MPLX has performed very well in Q1, delivering a performance of almost 20% in three months. Nevertheless, shares are not at all expensive, trading at a single-digitearningsmultiple - even though earnings are generally a lot lower than cash flows for pipeline companies due to non-cash depreciation charges. Management believes that the company will have ample surplus cash this year, even after making its hefty dividend payments.\nIts CEO stated that shares are undervalued and that the company will likely do&nbsp;buybacks&nbsp;this year, which is a major positive. This will not only be highly accretive thanks to the low valuation shares are trading at, but should also further support the price. Shares are a less outstanding buy compared to December (or&nbsp;earlier in 2020), but they still look very compelling, we believe. They also still offer a very attractive dividend yield of 11% at today's price.\n4. Enterprise Products\nLike MPLX, Enterprise Products has performed well so far this year, on the back of enthusiasm for energy-related names. Its profits and cash flows are not really tied to the price of oil, but the market still bid up shares in recent months. The same had been true in 2020 when shares were sold off in tandem with other energy names, even though Enterprise Products' cash flows were not really impacted by lower oil prices.\nShares are up by double-digits so far this year, but Enterprise Products' shares are not at all expensive. Considering that shares are trading at just around 7 times this year's distributable cash flows, while shares offer a dividend yield of 8.1%, makes us believe that this is still a strong pick for income investors. The fact that management has been buying back shares is another tailwind that could gain relevance as growth spending slows down, which should free up more money for buybacks going forward. We thus&nbsp;still like Enterprise Products&nbsp;as a high-quality midstream company at current prices.\n5. Prudential Financial\nThis insurer has had a very solid 2020 and seeks to generate even stronger profits this year. Shares are up by double-digits so far this year but do not look expensive. With current forecasts seeing the company earn about $11.50 per share this year, and even more next year, shares trade at a ~8 times forward earnings multiple right now. The company continues to reward shareholders handsomely, as Prudential has raised its dividend by 5% in February.\nAt current prices, the stock yields 5.1%, which is quite attractive in a low-yield world. Management plans to return a total of $10 billion to the company's owners through 2023, which equates to shareholder returns in the 10% range. Investors can thus count on more dividend increases down the road, coupled with some buybacks that will be quite accretive as long as shares continue to trade at an inexpensive valuation. Shares were a better buy in December, but they still look solid today.\n6. Citigroup\nCitigroup was the only bank on our list, and I mainly chose it over peers due to its below-average valuation and above-average dividend yield. 2021 has been great for bank stocks so far, due to an overall shift to value stocks, combined with rising interest spreads that are beneficial for banks' earnings.\nShares rose by double-digits so far this year, hitting a high of $76 about two weeks ago. At that price, shares were trading above tangible book value, which stands at $73.80 right now, which is why I sold part of my position in the mid-$70s. Nevertheless, I did not sell my entire stake, as I feel that shares could rise above that level at some point in 2021, even though they have pulled back a little for now.\nThe fact that banks are allowed to return more capital to their owners this year could become a catalyst for share price gains in 2021, as Citigroup will likely seek to increase its dividend and ramp up share repurchases. Trading marginally below tangible book value and at around 10 times this year's earnings, Citigroup is not at all expensive, although also not an absolute bargain any longer. I am moderately bullish, but wouldn't buy more at current valuations.\n7. Simon Property\nSimon Property is the leading mall player in the US, especially following the close of its acquisition of Taubman. The company had a harsh 2020, but its assets will, we believe, remain in use for a long time. High-quality malls in major metropolitan areas will not lose their value due to online shopping, as retail space can be used for more experimental retail, restaurants, bars, co-working spaces, hotels, and so on.\nThis was our thesis throughout 2020, which is why we were very bullish on the stock when it traded at ultra-low valuations last year. In 2021, shares have, so far, returned almost 30%, as the market is increasingly realizing that the pandemic was not the end for high-quality retail real estate such as the properties that Simon Property owns. Shares breached $120 earlier in March but have pulled back a little for now.\nTrading at ~11 times this year's FFO, Simon Property is not an absolute bargain stock any longer. I personally believe that shares will rise back towards pre-crisis levels of $150+ eventually, but that may take some time, and there is not necessarily massive upside left in 2021. I continue to hold my Simon Property position and am bullish with a long-term view, but the best time to add this stock wasin 2020 when it traded at double-digits.\n8. W. P. Carey\nUnlike Simon Property, W. P. Carey has not risen a lot this year. Instead, shares are down slightly, potentially due to the fact that real estate investors moved towards more cyclical picks in the sector for the reopening trade. W. P. Carey is a rock-solid, low-risk income stock that offers a yield of 6.0% right here and that trades at 15 times forward FFO. This is an above-average valuation compared to the other stocks in this list, but that seems justified based on the fact that W. P. Carey has always traded at higher valuations than most of these stocks.\nAs income investors can still not generate attractive yields from bonds, they will, I believe, eventually flock back towards low-risk REITs such as W. P. Carey or Realty Income (O), which could propel shares of these companies back to pre-crisis levels. In W. P. Carey's case, they traded at around $90 before the pandemic, which equates to a yield of around 4.5%. A recovery to that level does not seem unrealistic, I believe, which is why I continue to see W. P. Carey as a moderate-return, low-risk stock, which makes it attractive from a risk-to-reward perspective.\n9. AT&amp;T\nAT&amp;T remains a battleground stock, with bulls touting the undervaluation and potential in streaming, while bears focus on the high debt load. We do not see AT&amp;T as an extremely-high-quality pick, but the company's shares offer a solid yield of almost 7% and current management seems to have the right focus. Plans to monetize non-core assets, including DirecTV, are great, and the company plans to deleverage meaningfully over the coming years. AT&amp;T is not a high-growth company and will not turn into one, but the fact that the performance of HBO Max has&nbsp;beaten management's expectations&nbsp;is a positive for sure. At less than 10 times net profits, AT&amp;T remains quite inexpensive and if management executes on its plans, shares could deliver quite solid returns over the coming years.\n10. Intel\nIntel is a somewhat weird stock - the company executes well and grows steadily, but its shares see big swings up and down depending on whether investors are focusing on positive news items or negative news items at the moment. So far this year, they seem to do the prior, as shares have risen by 25% in just three months. This can't be explained by the underlying operational performance, which has been solid but didn't include growth of 20%+. Instead, the market is currently liking Intel's stock based on recent news such as a new CEO and plans to invest heavily to grow production capacity.\nI think the best time to buy Intel's shares is when the market is&nbsp;focusing on the bad news, whereas one may want to lock in gains when shares are trading at the top end of the recent valuation range. At 13.5 times forward earnings, Intel's shares trade at a premium to the median earnings multiple they have traded at over the last couple of years, thus I wouldn't buy here. Instead, locking in gains in the high $60s seemed like an opportune choice. I wouldn't be too surprised if shares fell back towards the mid-$50s or lower at some point during this year.\nTakeaway\nOur picks for 2020 have done very well so far, easily beating the market and even purely value-focused ETFs. However, not all of these stocks are necessarily still a great buy. I personally wouldn't buy Intel now, as the stock has already delivered easily more than 20% this year, and is trading at the higher end of the recent valuation range. On the other hand, some of our picks, such as AbbVie or W. P. Carey, are still priced very favorably and may even be a better buy right now compared to the beginning of the year.\nWe welcome you to share your comments on the above stocks, as well as your picks for the remainder of 2021!","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop 10 Undervalued Income Stocks For 2021 - Value Beats Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-26 23:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth>seekingalpha</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nSummary\n\nAt the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.\nIn this report, we examine the ...\n\n<a href=\"https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WPC":"W. P. Carey Inc","C":"花旗","EPD":"Enterprise Products Partners L.P","ABBV":"艾伯维公司","SPG":"西蒙地产","PFH":"Prudential Financial Inc","BMY":"施贵宝","MPLX":"MPLX LP","INTC":"英特尔","T":"美国电话电报"},"source_url":"https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1114428323","content_text":"Summary\n\nAt the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.\nIn this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.\nIn some cases, the opportunity is even better now, in others, it may be time to lock in some gains.\n\nPhoto by VeranikaSmirnaya/iStock via Getty Images\nWe wrote an article at the end of December in which we showcased 10 attractive income stocks that traded at inexpensive valuations back then. This resulted in a combination of upside potential and above-average income for investors that bought these stocks at the time. In this article, we will look again at the same ten stocks to see what has changed and whether they are all still attractive at current valuations.\nTop 10 Value Picks For Dividend Investors\nOur choices in our original article included the following 10 stocks:\n- Bristol-Myers Squibb (BMY) and AbbVie (ABBV) in healthcare\n- MPLX (MPLX) and Enterprise Products (EPD) in energy\n- Prudential (PRU) and Citigroup (C) in financials\n- Simon Property Group (SPG) and W. P. Carey (WPC) in real estate\n- AT&T (T) in telecommunication\n- Intel (INTC) in tech\nLooking back one quarter later, we see that shares have performed like this:\nData by YCharts\nYear-to-date, they delivered an average return of 12% and a median return of 15%. Contrast this with the year-to-date return of 3% that was delivered by the S&P 500 index (SPY), and we see that our picks clearly outperformed the broad market, delivering 4-5 times the performance enjoyed by those that put their money into the index.\n2020 Versus 2021: Growth Versus Value\nThis was, I believe, partially the result of investing in high-yielding stocks that traded at very inexpensive valuations and were thus undervalued, but the portfolio also benefited from an overall shift in the market's focus.\n2020 was the year of growth stocks, which saw many \"growthy\" tech names generate very attractive gains. The same could be said about EV stocks, renewable stocks, etc., which all flourished last year thanks to an appetite for growth stocks and unprecedented monetary stimulus. In 2021, that has changed to some degree:\nData by YCharts\nIn the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index (NASDAQ:QQQ) started to decline, underperforming the S&P 500 index this year, whereas the less techy, less growth-focused Dow Jones index (NYSEARCA:DIA) has beaten the S&P 500 so far in 2021. Looking at two ETFs that focus on either Value (VTV) or Growth(NYSEARCA:VUG), we see that the value theme clearly has been the winner so far this year, beating all three indexes, whereas the growth-themed ETF is down this year. The good news is that our basket of stocks still easily outperformed the Value ETF, which shows that we seem to have at least some skill when it comes to picking individual stocks (or maybe we got lucky).\nAre Those 10 Still Great Buys Today?\nSince some of these stocks have moved so much already in the first three months, they may not all be an opportune buy any longer, which is why we will take a quick look at all ten individually.\n1. AbbVie\nAbbVie was one of our two healthcare picks in the original article. The company combines many positives, including an above-average yield, a low valuation, and steady growth even during the pandemic. AbbVie's most recent quarterly results showcase its outstanding resilience during the current crisis: The company managed to grow its revenues across its portfolio, with Humira, Imbruvica, and its new drugs Skyrizi and Rinvoq showing a strong performance.\nEven better, the company guided earnings above consensus, forecasting earnings per share of $12.40 for the current year. Relative to its share price of $103, this means that shares got even cheaper since our December article, they are now trading for just 8.3 times forward earnings. In short, there is nothing not to like, and I believe that 5.1%-yielding AbbVie is a strong buy.\n2. Bristol-Myers Squibb\nBristol-Myers is the other healthcare pick in our original list. Like AbbVie, its shares were very inexpensive in December, and like AbbVie, it has continued to deliver strong operational results. Its most recent quarterly update included a 39% revenue growth rate compared to the previous year's quarter. This was impacted by one-time items from the Celgene takeover, but even adjusted for that, revenue growth came in at a strong 10% year over year.\nLike AbbVie, Bristol-Myers has also increased its earnings per share guidance for 2021, now forecasting profits of ~$7.30 per share. Since shares are essentially flat since the beginning of the year, investors get an even better deal right now in terms of Bristol-Myers' valuation, which stands at 8.3 times net profits right now. Bristol-Myers is also one of the stocks Berkshire Hathaway (BRK.A)(BRK.B) has continued to add to in the most recent quarter, which indicates that this is indeed a strong pick for value investors.\n3. MPLX\nMPLX is a natural gas midstream player that offered a great income yield in December, at almost 13%. On top of that, shares were very inexpensive, trading at a distributable cash flow yield of almost 19%.\nLike many other energy-related names, MPLX has performed very well in Q1, delivering a performance of almost 20% in three months. Nevertheless, shares are not at all expensive, trading at a single-digitearningsmultiple - even though earnings are generally a lot lower than cash flows for pipeline companies due to non-cash depreciation charges. Management believes that the company will have ample surplus cash this year, even after making its hefty dividend payments.\nIts CEO stated that shares are undervalued and that the company will likely do buybacks this year, which is a major positive. This will not only be highly accretive thanks to the low valuation shares are trading at, but should also further support the price. Shares are a less outstanding buy compared to December (or earlier in 2020), but they still look very compelling, we believe. They also still offer a very attractive dividend yield of 11% at today's price.\n4. Enterprise Products\nLike MPLX, Enterprise Products has performed well so far this year, on the back of enthusiasm for energy-related names. Its profits and cash flows are not really tied to the price of oil, but the market still bid up shares in recent months. The same had been true in 2020 when shares were sold off in tandem with other energy names, even though Enterprise Products' cash flows were not really impacted by lower oil prices.\nShares are up by double-digits so far this year, but Enterprise Products' shares are not at all expensive. Considering that shares are trading at just around 7 times this year's distributable cash flows, while shares offer a dividend yield of 8.1%, makes us believe that this is still a strong pick for income investors. The fact that management has been buying back shares is another tailwind that could gain relevance as growth spending slows down, which should free up more money for buybacks going forward. We thus still like Enterprise Products as a high-quality midstream company at current prices.\n5. Prudential Financial\nThis insurer has had a very solid 2020 and seeks to generate even stronger profits this year. Shares are up by double-digits so far this year but do not look expensive. With current forecasts seeing the company earn about $11.50 per share this year, and even more next year, shares trade at a ~8 times forward earnings multiple right now. The company continues to reward shareholders handsomely, as Prudential has raised its dividend by 5% in February.\nAt current prices, the stock yields 5.1%, which is quite attractive in a low-yield world. Management plans to return a total of $10 billion to the company's owners through 2023, which equates to shareholder returns in the 10% range. Investors can thus count on more dividend increases down the road, coupled with some buybacks that will be quite accretive as long as shares continue to trade at an inexpensive valuation. Shares were a better buy in December, but they still look solid today.\n6. Citigroup\nCitigroup was the only bank on our list, and I mainly chose it over peers due to its below-average valuation and above-average dividend yield. 2021 has been great for bank stocks so far, due to an overall shift to value stocks, combined with rising interest spreads that are beneficial for banks' earnings.\nShares rose by double-digits so far this year, hitting a high of $76 about two weeks ago. At that price, shares were trading above tangible book value, which stands at $73.80 right now, which is why I sold part of my position in the mid-$70s. Nevertheless, I did not sell my entire stake, as I feel that shares could rise above that level at some point in 2021, even though they have pulled back a little for now.\nThe fact that banks are allowed to return more capital to their owners this year could become a catalyst for share price gains in 2021, as Citigroup will likely seek to increase its dividend and ramp up share repurchases. Trading marginally below tangible book value and at around 10 times this year's earnings, Citigroup is not at all expensive, although also not an absolute bargain any longer. I am moderately bullish, but wouldn't buy more at current valuations.\n7. Simon Property\nSimon Property is the leading mall player in the US, especially following the close of its acquisition of Taubman. The company had a harsh 2020, but its assets will, we believe, remain in use for a long time. High-quality malls in major metropolitan areas will not lose their value due to online shopping, as retail space can be used for more experimental retail, restaurants, bars, co-working spaces, hotels, and so on.\nThis was our thesis throughout 2020, which is why we were very bullish on the stock when it traded at ultra-low valuations last year. In 2021, shares have, so far, returned almost 30%, as the market is increasingly realizing that the pandemic was not the end for high-quality retail real estate such as the properties that Simon Property owns. Shares breached $120 earlier in March but have pulled back a little for now.\nTrading at ~11 times this year's FFO, Simon Property is not an absolute bargain stock any longer. I personally believe that shares will rise back towards pre-crisis levels of $150+ eventually, but that may take some time, and there is not necessarily massive upside left in 2021. I continue to hold my Simon Property position and am bullish with a long-term view, but the best time to add this stock wasin 2020 when it traded at double-digits.\n8. W. P. Carey\nUnlike Simon Property, W. P. Carey has not risen a lot this year. Instead, shares are down slightly, potentially due to the fact that real estate investors moved towards more cyclical picks in the sector for the reopening trade. W. P. Carey is a rock-solid, low-risk income stock that offers a yield of 6.0% right here and that trades at 15 times forward FFO. This is an above-average valuation compared to the other stocks in this list, but that seems justified based on the fact that W. P. Carey has always traded at higher valuations than most of these stocks.\nAs income investors can still not generate attractive yields from bonds, they will, I believe, eventually flock back towards low-risk REITs such as W. P. Carey or Realty Income (O), which could propel shares of these companies back to pre-crisis levels. In W. P. Carey's case, they traded at around $90 before the pandemic, which equates to a yield of around 4.5%. A recovery to that level does not seem unrealistic, I believe, which is why I continue to see W. P. Carey as a moderate-return, low-risk stock, which makes it attractive from a risk-to-reward perspective.\n9. AT&T\nAT&T remains a battleground stock, with bulls touting the undervaluation and potential in streaming, while bears focus on the high debt load. We do not see AT&T as an extremely-high-quality pick, but the company's shares offer a solid yield of almost 7% and current management seems to have the right focus. Plans to monetize non-core assets, including DirecTV, are great, and the company plans to deleverage meaningfully over the coming years. AT&T is not a high-growth company and will not turn into one, but the fact that the performance of HBO Max has beaten management's expectations is a positive for sure. At less than 10 times net profits, AT&T remains quite inexpensive and if management executes on its plans, shares could deliver quite solid returns over the coming years.\n10. Intel\nIntel is a somewhat weird stock - the company executes well and grows steadily, but its shares see big swings up and down depending on whether investors are focusing on positive news items or negative news items at the moment. So far this year, they seem to do the prior, as shares have risen by 25% in just three months. This can't be explained by the underlying operational performance, which has been solid but didn't include growth of 20%+. Instead, the market is currently liking Intel's stock based on recent news such as a new CEO and plans to invest heavily to grow production capacity.\nI think the best time to buy Intel's shares is when the market is focusing on the bad news, whereas one may want to lock in gains when shares are trading at the top end of the recent valuation range. At 13.5 times forward earnings, Intel's shares trade at a premium to the median earnings multiple they have traded at over the last couple of years, thus I wouldn't buy here. Instead, locking in gains in the high $60s seemed like an opportune choice. I wouldn't be too surprised if shares fell back towards the mid-$50s or lower at some point during this year.\nTakeaway\nOur picks for 2020 have done very well so far, easily beating the market and even purely value-focused ETFs. However, not all of these stocks are necessarily still a great buy. I personally wouldn't buy Intel now, as the stock has already delivered easily more than 20% this year, and is trading at the higher end of the recent valuation range. On the other hand, some of our picks, such as AbbVie or W. P. Carey, are still priced very favorably and may even be a better buy right now compared to the beginning of the year.\nWe welcome you to share your comments on the above stocks, as well as your picks for the remainder of 2021!","news_type":1},"isVote":1,"tweetType":1,"viewCount":177,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/352627277"}